MacroGenics Reports 27% Response Rate in MGC026 Phase 1 Study
MacroGenics reported interim Phase 1 results showing a 27% response rate in heavily pretreated SCCHN patients and plans a front-line combination study with pembrolizumab.
MacroGenics reported encouraging interim Phase 1 results for MGC026, including a 27% response rate in heavily pretreated SCCHN patients, and plans a front-line combination study.Key Highlights:Original SEC Filing: MACROGENICS INC [ MGNX ] - 8-K - Oct. 23, 2026This is an AI-powered summary. It may c…